Featured Image

Science

Exosomes: Tiny Messengers with Big Potential in Diagnostics

Exosomes hold significant promise for diagnosing a broad range of diseases, including cancer, neurodegenerative, and infectious diseases, highlighting their versatility as diagnostic tools. As research progresses, several distinct advantages of exosomes over traditional diagnostic methods become evident.


 

Introduction to Exosomes

Exosomes are small, membrane-bound vesicles, typically measuring between 30 to 150 nanometers in diameter, that are secreted by various cell types into the extracellular environment. As a subset of extracellular vesicles, exosomes play a crucial role in facilitating intercellular communication. They are formed within a cell's endosomal system and released when multivesicular bodies (MVBs) fuse with the plasma membrane. Exosomes are involved in numerous biological processes, including immune responses, cell signaling, tissue repair, and the modulation of the tumor microenvironment.

 

Exosomes as Diagnostic Tools

 

Exosomes hold significant promise for diagnosing a broad range of diseases, including cancer, neurodegenerative, and infectious diseases, highlighting their versatility as diagnostic tools. As research progresses, several distinct advantages of exosomes over traditional diagnostic methods become evident. Firstly, exosomes exhibit high sensitivity by encapsulating a diverse array of biomolecules, enabling comprehensive molecular profiling and providing a more complete picture of disease states. Secondly, they demonstrate high specificity by carrying cell-specific biomarkers, resulting in precise diagnostic outcomes. Thirdly, the collection of exosomes is non-invasive and can be achieved through standard body fluid collection methods. This approach eliminates the need for tissue sectioning or puncture, simplifying the diagnostic process and enhancing patient comfort. Fourthly, exosomes maintain stability in various biological fluids such as blood, urine, and saliva, thereby preserving the integrity of their biomolecular content over time and making them reliable carriers of disease information. Fifthly, exosomes show promise for early disease detection; by reflecting cellular changes, they may detect diseases at an earlier stage than some traditional biomarkers, potentially leading to earlier intervention and improved outcomes. Sixthly, exosomes provide a real-time snapshot of biological processes and disease progression, facilitating dynamic monitoring of disease and treatment response through longitudinal studies. Lastly, exosomes offer ease of storage. Once collected, they can be preserved for extended periods through cryopreservation and other techniques, allowing for future analysis. Overall, these advantages make exosomes a compelling option in the field of in vitro diagnostics.

 

Table 1. Exosomal Biomarkers for the Early-stage Cancer Diagnosis

 

Cancer Type Exosomes Source Biomarker Selected Bioss Antibodies
Lung Cancer Plasma, NSCLC tissue, Pleural effusion EGFR, EpCam, Alix, K-ras, Basigin, Claudin1 bsm-52317R, bsm-60797R, bsm-60716R, bs-1033R, bsm-52837R, bsm-60433R
Liver Cancer Plasma, Serum 14-3-3 protein, G38p, Smad3 bs-0237R, bsm-62130R, bs-23580R
Pancreatic Cancer Serum MIF bs-1044R
Urinary Cancer HT1376 cell, Urine MUC1, Integrins β1, CD36, CD44, CD10, Basigin, CD73, bsm-51126M, bs-34248R, bsm-61310R, bsm-63050R, bsm-62909R, bsm-52837R, bsm-52916R
Ovary Cancer Serum, Ovary cancer tissue Her2, Hsp70, CD24, EpCam bsm-42263M, bsm-52241R, bs-4891R,
bsm-60797R
Thyroid Cancer Serum, Thyroid cancer Tissue Src, Hsp27, Hsp60, Hsp90 bs-10604R, bsm-52757R, bsm-61183R, bsm-52353R
Breast Cancer Plasma, Serum Fibronectin, ADAM10, CD9, Hsp70 bs-0666R, bs-22676R, bsm-52264R,
bsm-52241R
Gastric Cancer Plasma TGF-β1, EGFR bsm-61027R, bsm-52317R
Colorectal Cancer Plasma, CRC cell CEA, EGFR, MAPK4, EpCam, PCNA, Keratin 18, S100A8, Tenascin C, Src, KRAS bsm-43141M, bs-34018R, bs-4131R,
bsm-52417R, bsm-33035M, bsm-52058R, bsm-61167R, bsm-61165R, bs-10604R,
bs-1033R

Numerous studies have highlighted the potential of exosomes in detecting cancer and neurodegenerative diseases. These studies have successfully identified exosomes, emphasizing their promising role as diagnostic biomarkers due to their rich biological signatures and exceptional stability. Tables 1 and 2 provide a selective list of protein biomarkers and their corresponding detection antibodies, with Table 1 focusing on early-stage cancers (such as lung, breast, colon, liver, pancreatic, and gastric cancers) and Table 2 on neurodegenerative diseases. 

 

Table 2. Exosomal Biomarkers for Neurodegenerative Disease Diagnosis

 

Disease Exosomes
Source
Biomarker Selected Bioss Antibodies
Alzheimer's Disease Plasma, CSF Aβ42, Tau (pT181), Tau (pS396), Total-tau, Insulin receptor substrate 1, Cathepsin D, LAMP1, Synaptophysin, Synaptopodin, Neurogranin bsm-41470M, bs-8453R, bs-3446R, bsm-52301R, bs-22301R, bsm-61164R, bsm-61375R, bsm-52379R, bs-3446R, bs-3633R, bs-11435R
Parkinson's Disease Blood, Serum α-synuclein, fibrinogen, Clusterin, Complement C1r subcomponent, DJ1p, Apolipoprotein A-I bsm-0968M, bsm-62182R, bs-15086R, bsm-61297R, bsm-61232R
Prion Disease CSF Major Prion Protein, Tau, 14-3-3, Cystatin c bsm-52505R, bsm-60835R, bsm-52728R, bsm-61363R
Fronto-temporal Dementia Blood, CSF NF-L, Aβ42, Tau (pT181),Tau (pS396), Total-tau bsm-41217M, bsm-41470M, bs-8453R, bs-3446Rbsm-52301R
Amyotrophic Lateral Sclerosis Plasma, CSF, Serum TDP-43, NF-L, NF-H,SOD1, FUS bsm-60381M, bsm-41217M, bs-0708R, bsm-60838R, bsm-61371R

 

Challenges in Exosome-Based Diagnostics

 

While the potential benefits of using exosomes for disease diagnosis are promising, several substantial challenges hinder their widespread application. A primary concern is the lack of standardization in exosome collection and detection methods. Current techniques, including ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture, are often time-consuming and labor-intensive. These methods frequently struggle to fully separate exosomes from other extracellular vesicles or contaminants. Moreover, the technology required to accurately differentiate exosomes from other particles remains underdeveloped. Although various reagents, including specific antibodies (Table 3), have been designed to distinguish exosomes, isolating them precisely remains challenging, leading to unreliable and inaccurate quantification.

Furthermore, the biological complexity of exosomes adds an additional layer of complication. Factors such as age, diet, and medication can influence exosomal composition, complicating the interpretation of exosomal data for disease diagnosis. This variability underscores the need for more sophisticated and standardized methodologies to harness the full diagnostic potential of exosomes.

 

Table 3. Common Exosomal Biomarkers

 

Disease Exosomes Source Biomarker Selected Bioss Antibodies
Alzheimer's Disease Plasma, CSF Aβ42, Tau (pT181), Tau (pS396), Total-tau, Insulin receptor substrate 1, Cathepsin D, LAMP1, Synaptophysin, Synaptopodin, Neurogranin bsm-41470M, bs-8453R, bs-3446R, bsm-52301R, bs-22301R, bsm-61164R, bsm-61375R, bsm-52379R, bs-3446R, bs-3633R, bs-11435R
Parkinson's Disease Blood, Serum α-synuclein, fibrinogen, Clusterin, Complement C1r subcomponent, DJ1p, Apolipoprotein A-I bsm-0968M, bsm-62182R, bs-15086R, bsm-61297R, bsm-61232R
Prion Disease CSF Major Prion Protein, Tau, 14-3-3, Cystatin c bsm-52505R, bsm-60835R, bsm-52728R, bsm-61363R
Fronto-temporal Dementia Blood, CSF NF-L, Aβ42, Tau (pT181),Tau (pS396), Total-tau bsm-41217M, bsm-41470M, bs-8453R, bs-3446Rbsm-52301R
Amyotrophic Lateral Sclerosis Plasma, CSF, Serum TDP-43, NF-L, NF-H,SOD1, FUS bsm-60381M, bsm-41217M, bs-0708R, bsm-60838R, bsm-61371R

 

The Future of Exosome-Based Diagnostics

Exosomes represent a significant advancement in diagnostics, offering a non-invasive, precise, and dynamic modality for disease detection and monitoring. Due to their intrinsic advantages in sensitivity, specificity, and stability, exosomes hold considerable promise for revolutionizing diagnostic methodologies, especially for complex pathologies such as cancer and neurodegenerative disorders. Nevertheless, to fully harness their potential, it is imperative to address existing challenges in the standardization and optimization of isolation techniques, as well as the precise interpretation of exosomal data. Future research should prioritize the development of robust protocols and innovative technologies to overcome these obstacles, thereby facilitating the integration of exosome-based diagnostics into clinical practice. As the scientific community continues to elucidate the intricacies of exosome biology and refine analytical methods, exosomes are positioned to become pivotal in the evolution of personalized medicine, enabling earlier intervention, personalized treatment regimens, and enhanced patient outcomes.

 

 

References:

 

  1. Wang X, Huang J, Chen W, et al.The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer. Exp Mol Med 54, 1390–1400 (2022). doi: 10.1038/s12276-022-00855-4.
  2. Mathew B, Mansuri MS, Williams KR, et al. Exosomes as Emerging Biomarker Tools in Neurodegenerative and Neuropsychiatric Disorders-A Proteomics Perspective. Brain Sci. 2021 Feb 19;11(2):258. doi: 10.3390/brainsci11020258.
  3. Gurung, S., Perocheau, D., Touramanidou, L. et al.The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal 19, 47 (2021). doi: 10.1186/s12964-021-00730-1.
  4. Nihat D., A comprehensive review on recent advances in exosome isolation and characterization: Toward clinical applications. Translational Oncology 50 (2024). doi: 10.1016/j.tranon.2024.102121.
  5. Kalluri R, LeBleu VS. The biologyfunction, and biomedical applications of exosomes. Science. 2020 Feb 7;367(6478):eaau6977. doi: 10.1126/science.aau6977. PMID: 32029601; PMCID: PMC7717626.

 

__

 

Table 1. Exosomal Biomarkers for the Early-stage Cancer Diagnosis

 

Cancer Type Exosomes Source Biomarker Selected Bioss Antibodies
Lung Cancer Plasma, NSCLC tissue, Pleural effusion EGFR, EpCam, Alix, K-ras, Basigin, Claudin1 bsm-52317R, bsm-60797R, bsm-60716R, bs-1033R, bsm-52837R, bsm-60433R
Liver Cancer Plasma, Serum 14-3-3 protein, G38p, Smad3 bs-0237R, bsm-62130R, bs-23580R
Pancreatic Cancer Serum MIF bs-1044R
Urinary Cancer HT1376 cell, Urine MUC1, Integrins β1, CD36, CD44, CD10, Basigin, CD73, bsm-51126M, bs-34248R, bsm-61310R, bsm-63050R, bsm-62909R, bsm-52837R, bsm-52916R
Ovary Cancer Serum, Ovary cancer tissue Her2, Hsp70, CD24, EpCam bsm-42263M, bsm-52241R, bs-4891R,
bsm-60797R
Thyroid Cancer Serum, Thyroid cancer Tissue Src, Hsp27, Hsp60, Hsp90 bs-10604R, bsm-52757R, bsm-61183R, bsm-52353R
Breast Cancer Plasma, Serum Fibronectin, ADAM10, CD9, Hsp70 bs-0666R, bs-22676R, bsm-52264R,
bsm-52241R
Gastric Cancer Plasma TGF-β1, EGFR bsm-61027R, bsm-52317R
Colorectal Cancer Plasma, CRC cell CEA, EGFR, MAPK4, EpCam, PCNA, Keratin 18, S100A8, Tenascin C, Src, KRAS bsm-43141M, bs-34018R, bs-4131R,
bsm-52417R, bsm-33035M, bsm-52058R, bsm-61167R, bsm-61165R, bs-10604R,
bs-1033R

 

 

 

Table 1. Exosomal Biomarkers for the Early-stage Cancer Diagnosis

Cancer type

Exosomes Source

Biomarker

Selected Bioss Antibodies

Lung Cancer

Plasma, NSCLC tissue, Pleural effusion

EGFR, EpCam, Alix, K-ras, Basigin, Claudin1

bsm-52317R, bsm-60797R, bsm-60716R, bs-1033R, bsm-52837R, bsm-60433R

Liver Cancer

Plasma, Serum

14-3-3 protein, G38p, Smad3

bs-0237R, bsm-62130R , bs-23580R

Pancreatic Cancer

Serum

MIF

bs-1044R

Urinary Cancer

HT1376 cell, Urine

MUC1, Integrins β1, CD36, CD44, CD10, Basigin, CD73,

bsm-51126M, bs-34248R, bsm-61310R, bsm-63050R, bsm-62909R, bsm-52837R, bsm-52916R     

Ovary Cancer

Serum, Ovary cancer tissue

Her2, Hsp70, CD24, EpCam

bsm-42263M, bsm-52241R, bs-4891R, bsm-60797R

Thyroid Cancer

Serum, Thyroid cancer Tissue

Src, Hsp27, Hsp60, Hsp90

bs-10604R, bsm-52757R, bsm-61183R, bsm-52353R

Breast Cancer

Plasma, Serum

Fibronectin, ADAM10, CD9, Hsp70

bs-0666R, bs-22676R, bsm-52264R, bsm-52241R

Gastric Cancer

Plasma

TGF-β1, EGFR

bsm-61027R, bsm-52317R

Colorectal Cancer

Plasma, CRC cell

CEA, EGFR, MAPK4, EpCam, PCNA, Keratin 18, S100A8, Tenascin C, Src, KRAS

bsm-43141M, bs-34018R, bs-4131R, bsm-52417R, bsm-33035M, bsm-52058R, bsm-61167R, bsm-61165R, bs-10604R, bs-1033R

 

 

Numerous studies have highlighted the potential of exosomes in detecting cancer and neurodegenerative diseases. These studies have successfully identified exosomes, emphasizing their promising role as diagnostic biomarkers due to their rich biological signatures and exceptional stability. Tables 1 and 2 provide a selective list of protein biomarkers and their corresponding detection antibodies, with Table 1 focusing on early-stage cancers (such as lung, breast, colon, liver, pancreatic, and gastric cancers) and Table 2 on neurodegenerative diseases. 

 

 Table 2. Exosomal Biomarkers for Neurodegenerative Disease Diagnosis

 

Disease Exosomes
Source
Biomarker Selected Bioss Antibodies
Alzheimer's Disease Plasma, CSF Aβ42, Tau (pT181), Tau (pS396), Total-tau, Insulin receptor substrate 1, Cathepsin D, LAMP1, Synaptophysin, Synaptopodin, Neurogranin bsm-41470M, bs-8453R, bs-3446R, bsm-52301R, bs-22301R, bsm-61164R, bsm-61375R, bsm-52379R, bs-3446R, bs-3633R, bs-11435R
Parkinson's Disease Blood, Serum α-synuclein, fibrinogen, Clusterin, Complement C1r subcomponent, DJ1p, Apolipoprotein A-I bsm-0968M, bsm-62182R, bs-15086R, bsm-61297R, bsm-61232R
Prion Disease CSF Major Prion Protein, Tau, 14-3-3, Cystatin c bsm-52505R, bsm-60835R, bsm-52728R, bsm-61363R
Fronto-temporal Dementia Blood, CSF NF-L, Aβ42, Tau (pT181),Tau (pS396), Total-tau bsm-41217M, bsm-41470M, bs-8453R, bs-3446Rbsm-52301R
Amyotrophic Lateral Sclerosis Plasma, CSF, Serum TDP-43, NF-L, NF-H,SOD1, FUS bsm-60381M, bsm-41217M, bs-0708R, bsm-60838R, bsm-61371R

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Table 2. Exosomal Biomarkers for Neurodegenerative Disease Diagnosis

Disease

Exosomes Source

Biomarker

Selected Bioss Antibodies

Alzheimer's Disease

Plasma, CSF
Aβ42, Tau (pT181), Tau (pS396), Total-tau, Insulin receptor substrate 1, Cathepsin D, LAMP1, Synaptophysin, Synaptopodin, Neurogranin

Parkinson's Disease

Blood, Serum
α-synuclein, fibrinogen, Clusterin, Complement C1r subcomponent, DJ1p, Apolipoprotein A-I

bsm-0968M, bsm-62182R, bs-15086R, bsm-61297R, bsm-61232R

Prion Disease

CSF

Major Prion Protein, Tau, 14-3-3, Cystatin c

bsm-52505R, bsm-60835R, bsm-52728R, bsm-61363R

Fronto-temporal Dementia

Blood, CSF NF-L, Aβ42, Tau (pT181),Tau (pS396), Total-tau

bsm-41217M, bsm-41470M, bs-8453R, bs-3446Rbsm-52301R

Amyotrophic Lateral Sclerosis

Plasma, CSF, Serum TDP-43, NF-L, NF-H,SOD1, FUS bsm-60381M, bsm-41217M, bs-0708R, bsm-60838R, bsm-61371R

 

Challenges in Exosome-Based Diagnostics

 

While the potential benefits of using exosomes for disease diagnosis are promising, several substantial challenges hinder their widespread application. A primary concern is the lack of standardization in exosome collection and detection methods. Current techniques, including ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture, are often time-consuming and labor-intensive. These methods frequently struggle to fully separate exosomes from other extracellular vesicles or contaminants. Moreover, the technology required to accurately differentiate exosomes from other particles remains underdeveloped. Although various reagents, including specific antibodies (Table 3), have been designed to distinguish exosomes, isolating them precisely remains challenging, leading to unreliable and inaccurate quantification.

Furthermore, the biological complexity of exosomes adds an additional layer of complication. Factors such as age, diet, and medication can influence exosomal composition, complicating the interpretation of exosomal data for disease diagnosis. This variability underscores the need for more sophisticated and standardized methodologies to harness the full diagnostic potential of exosomes.

 

 

Table 3. Common Exosomal Biomarkers

Category

Biomarker

Role

Selected Bioss Antibodies

Tetraspanins

CD9, CD63, CD81, CD82, CD53

Exosome biogenesis, exosome cargo selection, targeting and uptake bsm-52264R, bsm-60749R, bsm52640R, bsm-61627R, bsm-61803R

ESCRT machinery / MVB biogenesis

Alix, TSG-101

Exosome biogenesis bsm-60716R, bsm-52746R

Heat-shock proteins

Hsp90, Hsc70, Hsp60, Hsp20, Hsp27

Exosome release, signaling bsm-61128R, bsm-52241R, bsm-61183R, bsm-60365M, bsm-52757R

Membrane transport and fusion

Rab GTPases, Annexins, Flotillin, Dynamin, Syntaxin

Exosome secretion and uptake bsm-62025R, bsm-61849R, bsm-61169R, bsm-62476R, bsm-61620R, bsm-62368R

Cytoskeletal proteins

Actin, Cofilin, Tubulin

Exosome biogenesis and secretion bsm-52832R, bsm-60604R, bsm-61711R

 

The Future of Exosome-Based Diagnostics

Exosomes represent a significant advancement in diagnostics, offering a non-invasive, precise, and dynamic modality for disease detection and monitoring. Due to their intrinsic advantages in sensitivity, specificity, and stability, exosomes hold considerable promise for revolutionizing diagnostic methodologies, especially for complex pathologies such as cancer and neurodegenerative disorders. Nevertheless, to fully harness their potential, it is imperative to address existing challenges in the standardization and optimization of isolation techniques, as well as the precise interpretation of exosomal data. Future research should prioritize the development of robust protocols and innovative technologies to overcome these obstacles, thereby facilitating the integration of exosome-based diagnostics into clinical practice. As the scientific community continues to elucidate the intricacies of exosome biology and refine analytical methods, exosomes are positioned to become pivotal in the evolution of personalized medicine, enabling earlier intervention, personalized treatment regimens, and enhanced patient outcomes.

 

 

 

References:

 

  1. Wang X, Huang J, Chen W, et al.The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer. Exp Mol Med 54, 1390–1400 (2022). doi: 10.1038/s12276-022-00855-4.
  2. Mathew B, Mansuri MS, Williams KR, et al. Exosomes as Emerging Biomarker Tools in Neurodegenerative and Neuropsychiatric Disorders-A Proteomics Perspective. Brain Sci. 2021 Feb 19;11(2):258. doi: 10.3390/brainsci11020258.
  3. Gurung, S., Perocheau, D., Touramanidou, L. et al.The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal 19, 47 (2021). doi: 10.1186/s12964-021-00730-1.
  4. Nihat D., A comprehensive review on recent advances in exosome isolation and characterization: Toward clinical applications. Translational Oncology 50 (2024). doi: 10.1016/j.tranon.2024.102121.
  5. Kalluri R, LeBleu VS. The biologyfunction, and biomedical applications of exosomes. Science. 2020 Feb 7;367(6478):eaau6977. doi: 10.1126/science.aau6977. PMID: 32029601; PMCID: PMC7717626.

Similar posts